It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest.

Ocugen says it is on track to reshape the market for gene therapies against eye disorders over the next three years, by ...

CoreWeave purchased a research & development building at the NEST campus in Kenilworth, N.J., plus an adjacent 27 acres for ...

The U.S. trade deficit narrowed in June on a sharp drop in consumer goods imports, and the trade gap with China shrank to its ...

Pfizer is starting to execute on its turnaround plan and drug pipeline. 10 stocks we like better than Pfizer › Shares of the ...

Live Updates Live Coverage Updates appear automatically as they are published. Investors Don't Like the Taste of Yum! 9:37 am ...

BioMarin's strong revenue growth, pipeline expansions, and strategic acquisitions position it for success. Read more on the ...

The online weight loss company launches a $119 starter plan using low-dose semaglutide and behavioral coaching to improve ...

Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not ...

Hims & Hers stock (NASDAQ: HIMS) fell approximately 13% in after-hours trading following Q2 results that demonstrated strong ...

Y-mAbs Therapeutics ( NASDAQ: YMAB) is set to go private after SERB Pharmaceuticals announced on Tuesday that it would buy the cancer drug developer for an estimated $412M in equity value. The stock ...

President Trump said he will announce tariffs on semiconductors and pharmaceuticals "within the next week or so." "We're going to be announcing on semiconductors and chips," Trump said on CNBC on ...